[{"orgOrder":0,"company":"Accent Therapeutics","sponsor":"EcoR1 Capital ","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Series B Financing","leadProduct":"METTL3","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Accent Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Accent Therapeutics \/ EcoR1 Capital ","highestDevelopmentStatusID":"1","companyTruncated":"Accent Therapeutics \/ EcoR1 Capital "},{"orgOrder":0,"company":"Accent Therapeutics","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"METTL3","graph1":"Oncology","graph2":"Preclinical","graph3":"Accent Therapeutics","amount2":0.45000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.45000000000000001,"dosageForm":"","sponsorNew":"Accent Therapeutics \/ Ipsen","highestDevelopmentStatusID":"4","companyTruncated":"Accent Therapeutics \/ Ipsen"},{"orgOrder":0,"company":"Accent Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Accent Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Accent Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Accent Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Accent Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Series C Financing","leadProduct":"ATX968","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Accent Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Accent Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"5","companyTruncated":"Accent Therapeutics \/ Bristol Myers Squibb"}]

Find Clinical Drug Pipeline Developments & Deals by Katayama Seiyakusyo

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The net proceeds will support Accent's first-in-class DHX9 inhibitor for triple-negative breast cancer and ovarian cancer, alongside a potentially best-in-class KIF18A inhibitor.

                          Brand Name : ATX968

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          January 23, 2024

                          Lead Product(s) : ATX968

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Bristol Myers Squibb

                          Deal Size : $75.0 million

                          Deal Type : Series C Financing

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The presentation will describe the first identification of potent and selective small molecule inhibitors of DHX9 that demonstrate tumor cell killing in both in vitro and in vivo preclinical cancer models.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 06, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : This collaboration combines Accent’s expertise in RMP-targeting therapeutics with Ipsen’s capabilities and proven track record in Oncology medicine development and commercialization.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          October 18, 2021

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Ipsen

                          Deal Size : $446.0 million

                          Deal Type : Collaboration

                          blank

                          04

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Proceeds from the financing will be used to advance the development of Accent’s novel therapies targeting RNA-modifying proteins (RMPs), including its lead programs METTL3 and ADAR1.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          April 23, 2020

                          Lead Product(s) : METTL3

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Sponsor : EcoR1 Capital

                          Deal Size : $63.0 million

                          Deal Type : Series B Financing

                          blank